Yeah but, no but ... [Two-Stage / GS Designs]

posted by Helmut Homepage – Vienna, Austria, 2012-08-07 17:14 (5072 d 06:24 ago) – Posting: # 9047
Views: 17,466

Dear Detlew!

❝ ❝ […] If one follows Method B, IMHO a posteriori simulations are not necessary if the study was planned with a n1 corresponding to max. αemp.. That would mean that we are already on ‘top of the ridge’.


❝ Beeing on the ‘top of the ridge’ would mean IMHO that we are practically working with alpha1,2 = 0.0294.


Exactly. That’s what I mean by “if the study was planned with a n1 corresponding to max. αemp. above.

❝ Another rather clear message of this nice picture: Don't use n1 as low as 12 ('internal pilot' in the usual understanding of many sponsors) if the anticipated CV is >25%.


Yep. I was always preaching (though in the context of ‘classical’ pilot studies) against too small sample sizes if the anticipated CV is large.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,572 registered users;
327 visitors (0 registered, 327 guests [including 19 identified bots]).
Forum time: 23:38 CEST (Europe/Vienna)

Don’t compromise yourself.
You are all you’ve got.    Janis Joplin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5